MBX Biosciences, Inc. (MBX): Total Assets
$385.14M
As of 2025-12-31
$435.91M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $385.14M | +43.4% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $268.54M | +219.0% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $84.18M | n/a | 2025-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $385.14M | +43.4% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $383.53M | +18.7% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $393.09M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $396.15M | -21.2% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
Compare MBX, ZBIO, XERS, TRDA side by side · Screen every company in Pharmaceutical Preparations ↗